Stockman Wealth Management Inc. cut its stake in Merck & Co., Inc. (NYSE:MRK) by 1.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 82,942 shares of the company’s stock after selling 1,408 shares during the period. Merck & Co., Inc. makes up 2.8% of Stockman Wealth Management Inc.’s holdings, making the stock its 4th largest position. Stockman Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $6,955,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. LFA Lugano Financial Advisors SA lifted its position in Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after buying an additional 225 shares in the last quarter. JJJ Advisors Inc. bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Cumberland Partners Ltd bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $40,000. PRW Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $41,000. Finally, Fusion Family Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.
In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the transaction, the executive vice president now owns 103,223 shares in the company, valued at approximately $8,783,245.07. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the transaction, the chief financial officer now owns 354,378 shares in the company, valued at approximately $30,274,512.54. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.
Shares of NYSE:MRK traded down $0.05 on Tuesday, reaching $85.83. 3,425,899 shares of the company’s stock were exchanged, compared to its average volume of 9,356,066. The company has a fifty day moving average of $83.49 and a 200-day moving average of $81.33. Merck & Co., Inc. has a twelve month low of $66.10 and a twelve month high of $87.25. The company has a market capitalization of $217.48 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 1.73 and a beta of 0.56. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion for the quarter, compared to analyst estimates of $10.94 billion. During the same quarter in the prior year, the business posted $1.06 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. As a group, equities research analysts forecast that Merck & Co., Inc. will post 4.91 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.56%. Merck & Co., Inc.’s payout ratio is presently 50.69%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: What are Institutional Investors?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.